Participated · Series B · Jun 2026

Ona Therapeutics is a spin-off from IRB Barcelona and ICREA that develops precision-engineered antibody-drug conjugates (ADCs) to target treatment-resistant cancers. The company uses a proprietary, patient-driven discovery platform to identify tumor-specific antigens and epitopes that enable efficient internalization and targeted payload delivery. Its lead clinical program is ONA-255, initially focused on breast cancer, and it is also advancing ONA-389 targeting colorectal cancer. The company integrates target validation, antibody engineering, optimized payload selection and validated linker-payload technologies in its ADC development approach. Led by CEO Valerie Vanhooren, Ona plans to use the Series B proceeds to advance clinical development of its lead and second programs. The article does not disclose revenue, user metrics or a company valuation.

Led · Equity · Mar 2026

Entrix builds and operates a portfolio of battery storage systems across core European markets, offering end-to-end optimisation and market participation. Its platform manages more than 70 systems and a contracted capacity of 3 GW / 8.5 GWh, with 2 GW expected to be operational in 2026. Entrix runs local teams and offices in Germany, Italy, Spain and Poland, with Germany as its largest market by capacity. The company uses AI-driven trading and optimisation to participate in balancing services, day-ahead and intraday markets, translating battery performance into revenue. Founded in 2021, Entrix has grown from running one of Germany’s first large-scale battery projects into a sizable flexibility operator that it says is equivalent in scale to roughly three nuclear power plants or the peak demand of about three million households.

Led · Seed · Jan 2025

Commit Biologics is developing the Bispecific Complement Engaging (BiCE™) platform, a modular system that uses single‑domain antibodies to engage C1q and direct complement activation against tumor and autoimmune targets. The technology can arm conventional antibodies to enhance complement‑mediated cytotoxicity and modulate innate and adaptive immune responses. Commit spun out of Aarhus University and builds on more than three decades of research. Since emerging from stealth last May, the company has progressed its platform toward drug candidate selection. Proceeds from the recent financing will be used to advance BiCE and work toward drug candidate (DC) selection. The company says the extension of funding extends its cash runway into late 2026. Commit Biologics develops therapies that activate the complement system to kill specific target cells, with applications in cancer and autoimmune disease. Its core product is the Bispecific Complement Engaging (BiCE™) platform, a modular system that can arm antibodies to direct the complement system to selectively kill cancer cells or immune cells that drive autoimmune diseases. The platform is designed to leverage established antibodies, which the company says can cut development times and reduce risk. Commit plans to use the €16M seed financing to accelerate development of the BiCE™ platform. The company was spun out of Aarhus University and builds on more than three decades of research into complement biology. Commit is led by CEO Krishna Polu. Commit Biologics is developing the BiCE technology to fight cancer. The company announced it has received a 5M DKK Innobooster grant from the Innovation Fund Denmark (IFD). The grant is intended to support further development of the BiCE technology. Aarhus University Technology Transfer posted congratulations on LinkedIn about the boost. The funding is presented as an Innobooster grant rather than equity or debt; no additional financial details were disclosed in the article.

Led · Series B · Oct 2024

OroraTech operates a Wildfire Solution platform that ingests high-resolution thermal data from proprietary and public satellites to deliver real-time situational awareness and risk alerts. The company designs and operates nano-satellites and data pipelines to detect fires day or night and convert raw thermal data into actionable intelligence. It currently has ten satellites in orbit and a team of more than 140, and operates across Germany, the US, Australia, Brazil, Canada and Greece. OroraTech aims to deliver the world’s most persistent and comprehensive thermal data stream and to create a global “wildfire digital twin” capable of simulating future fire behavior. In the past year the company has signed close to €100 million in commercial contracts and venture capital, and recently extended its Series B financing. OroraTech develops space-based wildfire intelligence using thermal-infrared imaging satellites and analytics to offer near-real-time monitoring of at-risk lands. The company currently operates two of its own satellites and monitors about 160 million hectares of forest. It initially used data from dozens of other imaging satellites and terrestrial sources but now relies on its own sensors and plans an initial constellation of eight satellites by mid-2025. OroraTech has commercial deployments watching properties and lands in North America and the Pacific and secured a €20 million ESA contract to monitor Greece’s forests. The additional data they collect is intended to improve their predictive AI and overall service quality. The company recently raised a €25M (≈$27M) Series B to expand its sensor network and accelerate product development; FOREST-3 is expected to launch in early 2025. OroraTech builds and operates space-based thermal‑infrared cameras that deliver data in long‑wave infrared (LWIR) and medium‑wave infrared (MWIR) bands. Its LWIR sensors capture ambient temperatures while MWIR enables detection of very hot objects such as fires. The company’s first product, the Wildfire Intelligence Solution, detects over 100,000 fires each day and protects more than 160 million hectares across six continents. OroraTech plans to use the new funding to expand its climate solutions portfolio and to launch a second thermal‑infrared camera in space in May 2023. Headquartered in Munich, the company expanded its footprint in 2022 with experts in the US, Canada, and Luxembourg. The team is led by CEO Thomas Grübler. OroraTech develops a space-based wildfire warning system using small satellites equipped with custom infrared cameras and onboard machine-learning processing. The service aims to detect fires as small as 10 meters across and report them within half an hour. To validate the product it has been using data from more than a dozen satellites already in orbit. With new funding it will launch a shoebox-sized satellite carrying a custom IR sensor via Spire later this year and plans 14 more satellites by 2023. The company ultimately aims for a constellation of about 100 satellites to provide near-global coverage of high-risk regions. OroraTech was spun out of research by its founders at TUM, which retains an interest.

Participated · Series A · Sep 2024

PanTera leverages a patented photo-nuclear “gamma” production process to transform Radium-226 into Radium-225, which decays into clinical-grade actinium-225 (225Ac). The company aims to enable annual production of more than 100 Curies of clinical-grade 225Ac by 2029, supporting treatment of over 100,000 patients per year. PanTera plans to bring its commercial production facility online in Belgium, funded in part by the recent raise. In parallel, it is supplying early quantities of 225Ac via an alternative production method and, working with TerraPower Isotopes, expects to provide 1.5–2 Ci annually from early 2025. The company has signed supply agreements with several pharmaceutical companies, including Bayer, and expects to have secured agreements for more than 80% of its capacity before production starts. PanTera is led by CEO Sven Van den Berghe.